Literature DB >> 12381906

Long-term mortality of women with a diagnosis of breast cancer.

Fabio Levi1, Lalao Randimbison, Van-Cong Te, Carlo La Vecchia.   

Abstract

Survival from breast cancer has improved over the last few years, but scanty information is available on the long-term follow-up. We therefore considered data on 1,095 women with breast cancer diagnosed between 1974 and 1984 in the Swiss Cancer Registry of Vaud (population 616,000 inhabitants) who had survived for at least 10 years. Overall, 129 deaths from breast cancer were observed 10-19 years after the original diagnosis, corresponding to a standardized mortality ratio (SMR) of 20.3 (95% confidence interval (CI) 17.0-24.2). An excess mortality from breast cancer was observed 10-14 (SMR = 22.6) and 15-19 (SMR = 13.4) years after the original diagnosis. The SMR was 25.2 for women diagnosed with breast cancer at age <60 years. Consequently, total mortality was also elevated (SMR = 2.0, based on 294 deaths). None of the other causes of death was significantly elevated, but mortality from cardiovascular disease was 1.4 (95% CI 0.9-2.0) 15-19 years after breast cancer diagnosis. A second primary breast cancer was observed in 89 women. Of these, 19 (21%) died of breast cancer. Therefore in women diagnosed with breast cancer, there remains a substantial excess of breast cancer mortality up to 20 years after the original diagnosis. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12381906     DOI: 10.1159/000065475

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.

Authors:  Susan K Parsons; Michael J Kelly; Joshua T Cohen; Sharon M Castellino; Tara O Henderson; Kara M Kelly; Frank G Keller; Tobi J Henzer; Anita J Kumar; Peter Johnson; Ralph M Meyer; John Radford; John Raemaekers; David C Hodgson; Andrew M Evens
Journal:  Br J Haematol       Date:  2018-04-29       Impact factor: 6.998

2.  Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.

Authors:  Christos Markopoulos; Urania Dafni; John Misitzis; Vasilios Zobolas; Evagelos Tzoracoleftherakis; Dimitrios Koukouras; Grigorios Xepapadakis; John Papadiamantis; Basileios Venizelos; Zoh Antonopoulou; Helen Gogas
Journal:  Breast Cancer Res       Date:  2009-06-16       Impact factor: 6.466

Review 3.  The effects of aromatase inhibitors on lipids and thrombosis.

Authors:  N J Bundred
Journal:  Br J Cancer       Date:  2005-08       Impact factor: 7.640

4.  Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

Authors:  S Sehdev; G Martin; L Sideris; W Lam; S Brisson
Journal:  Curr Oncol       Date:  2009-07       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.